ATE526345T1 - Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheit - Google Patents
Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheitInfo
- Publication number
- ATE526345T1 ATE526345T1 AT06790622T AT06790622T ATE526345T1 AT E526345 T1 ATE526345 T1 AT E526345T1 AT 06790622 T AT06790622 T AT 06790622T AT 06790622 T AT06790622 T AT 06790622T AT E526345 T1 ATE526345 T1 AT E526345T1
- Authority
- AT
- Austria
- Prior art keywords
- antibody
- diagnosis
- prevention
- treatment
- antibodies
- Prior art date
Links
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 title abstract 3
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 title abstract 3
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/90283—Oxidoreductases (1.) acting on superoxide radicals as acceptor (1.15)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71240005P | 2005-08-31 | 2005-08-31 | |
| PCT/CA2006/001444 WO2007025385A1 (en) | 2005-08-31 | 2006-08-31 | Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE526345T1 true ATE526345T1 (de) | 2011-10-15 |
Family
ID=37808437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06790622T ATE526345T1 (de) | 2005-08-31 | 2006-08-31 | Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheit |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8759029B2 (de) |
| EP (1) | EP1937827B1 (de) |
| JP (1) | JP5242396B2 (de) |
| AT (1) | ATE526345T1 (de) |
| CA (1) | CA2620351C (de) |
| DK (1) | DK1937827T3 (de) |
| ES (1) | ES2374102T3 (de) |
| WO (1) | WO2007025385A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1668369B1 (de) | 2003-08-20 | 2016-01-06 | ProMIS Neurosciences Inc. | Epitopschutztest und verfahren zum nachweis von proteinkonformationen |
| US7794692B2 (en) | 2005-12-02 | 2010-09-14 | Amorfix Life Sciences Ltd. | Methods and compositions for detecting amyotrophic lateral sclerosis |
| US7887803B2 (en) | 2005-12-02 | 2011-02-15 | Amorfix Life Sciences | Methods and compositions to treat misfolded-SOD1 mediated diseases |
| EP2514824A3 (de) * | 2006-03-03 | 2013-01-23 | Amorfix Life Sciences Ltd. | Verfahren und Zusammensetzungen zum Behandeln und Erkennen von missgefaltetem SOD 1-herbeigeführte Erkrankungen |
| WO2010056732A1 (en) | 2008-11-12 | 2010-05-20 | Marv Enterprises Llc | Utilization of stents for the treatment of blood borne carcinomas |
| WO2010107789A1 (en) * | 2009-03-17 | 2010-09-23 | Marv Enterprises Llc | Sequential extracorporeal treatment of bodily fluids |
| WO2011041582A2 (en) | 2009-09-30 | 2011-04-07 | President And Fellows Of Harvard College | Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products |
| JP5828521B2 (ja) * | 2010-05-13 | 2015-12-09 | 国立大学法人 東京大学 | 筋萎縮性側索硬化症（ａｌｓ）の診断のための抗体 |
| EP2632952A4 (de) * | 2010-10-26 | 2014-04-30 | Univ Massachusetts | Antikörper gegen sod1 und anwendungen davon |
| WO2012080518A1 (en) | 2010-12-17 | 2012-06-21 | Neurimmune Holding Ag | Human anti-sod1 antibodies |
| US20220089704A1 (en) | 2018-10-29 | 2022-03-24 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
| EP4397766A1 (de) * | 2021-09-02 | 2024-07-10 | Kyoto University | Pharmazeutische zusammensetzung mit bornavirus-vektor |
| JPWO2023033049A1 (de) * | 2021-09-02 | 2023-03-09 | ||
| CN113774089A (zh) * | 2021-10-11 | 2021-12-10 | 深圳大学 | 肌萎缩侧索硬化细胞模型细胞株的构建方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4940659A (en) | 1987-02-20 | 1990-07-10 | Monoclonetics International, Inc. | Screening extra-cellular body fluids for superoxide dismutase (SOD-1) for determining fetal trisomy 21 down syndrome |
| US5843641A (en) | 1993-02-26 | 1998-12-01 | Massachusetts Institute Of Technology | Methods for the daignosis, of familial amyotrophic lateral sclerosis |
| US5780489A (en) | 1996-08-21 | 1998-07-14 | Brooks; Benjamin Rix | Method for treating amyotrophic lateral sclerosis |
| US6420429B1 (en) | 1997-12-23 | 2002-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Brain targeted low molecular weight hydrophobic antioxidant compounds |
| EP1668369B1 (de) | 2003-08-20 | 2016-01-06 | ProMIS Neurosciences Inc. | Epitopschutztest und verfahren zum nachweis von proteinkonformationen |
-
2006
- 2006-08-31 US US12/065,403 patent/US8759029B2/en not_active Expired - Fee Related
- 2006-08-31 JP JP2008528307A patent/JP5242396B2/ja not_active Expired - Fee Related
- 2006-08-31 CA CA2620351A patent/CA2620351C/en not_active Expired - Fee Related
- 2006-08-31 EP EP06790622A patent/EP1937827B1/de active Active
- 2006-08-31 ES ES06790622T patent/ES2374102T3/es active Active
- 2006-08-31 AT AT06790622T patent/ATE526345T1/de active
- 2006-08-31 WO PCT/CA2006/001444 patent/WO2007025385A1/en active Application Filing
- 2006-08-31 DK DK06790622.2T patent/DK1937827T3/da active
-
2014
- 2014-05-27 US US14/288,374 patent/US9266963B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1937827A4 (de) | 2009-02-18 |
| US8759029B2 (en) | 2014-06-24 |
| DK1937827T3 (da) | 2012-01-23 |
| CA2620351C (en) | 2015-04-21 |
| EP1937827A1 (de) | 2008-07-02 |
| JP2009507475A (ja) | 2009-02-26 |
| JP5242396B2 (ja) | 2013-07-24 |
| US20140341927A1 (en) | 2014-11-20 |
| CA2620351A1 (en) | 2007-03-08 |
| ES2374102T3 (es) | 2012-02-13 |
| WO2007025385A1 (en) | 2007-03-08 |
| EP1937827B1 (de) | 2011-09-28 |
| US9266963B2 (en) | 2016-02-23 |
| US20090068194A1 (en) | 2009-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE526345T1 (de) | Antikörper und ihre verwendung bei der behandlung,vorbeugung und diagnose einer mit sod1-anomalien assoziierten krankheit | |
| PH12011502389A1 (en) | Monoclonal antibody | |
| MA30632B1 (fr) | Anticorps humanisé | |
| MX2009013503A (es) | Anticuerpo monoclonal anti-amiloide-beta. | |
| MX2022005782A (es) | Anticuerpos monoclonales contra la proteina amiloide beta y usos de los mismos. | |
| MX2009004532A (es) | Composiciones y metodos para unir esfingosina-1-fosfato. | |
| WO2010009987A3 (en) | Diagnostic antibody assay | |
| WO2008060364A3 (en) | Humani zed antibody against amyloid beta | |
| WO2007011907A3 (en) | Alpha-synuclein antibodies and methods related thereto | |
| MA35174B1 (fr) | Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines | |
| SG10201407388XA (en) | Humanized anti-cxcr5 antibodies, derivatives thereof and their uses | |
| WO2010012004A3 (en) | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence | |
| WO2007011834A3 (en) | Compounds and method for the diagnosis and treatment of amyloid associated diseases | |
| MX2007013626A (es) | Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos. | |
| UA103499C2 (ru) | Антитело против интерлейкина-17 (ил-17) человека и его применение | |
| EA200870050A1 (ru) | Анти-il-17-антитела | |
| WO2006040153A3 (en) | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease | |
| WO2005025516A3 (en) | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates | |
| MA33825B1 (fr) | Analogue du peptide d'oxyntomoduline | |
| GB0603683D0 (en) | Organic compounds | |
| PE20100684A1 (es) | Anticuerpo anti b-4-amiloide que contiene asparagina glicosilada en la region variable de vh | |
| WO2011045415A3 (en) | Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases | |
| MY156353A (en) | Methods of treating autoimmune diseases with dll4 antagonists | |
| EA201070539A1 (ru) | НОВЫЕ АНТИТЕЛА, СПЕЦИФИЧНЫЕ К β-АМИЛОИДНЫМ ПЕПТИДАМ, И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ДИАГНОСТИЧЕСКИХ ИЛИ ЛЕКАРСТВЕННЫХ СРЕДСТВ | |
| EA200801343A1 (ru) | Иммуноглобулины, направленные против nogo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1937827 Country of ref document: EP |